160 related articles for article (PubMed ID: 15110187)
1. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.
Holoch PA; Griffith TS
Eur J Pharmacol; 2009 Dec; 625(1-3):63-72. PubMed ID: 19836385
[TBL] [Abstract][Full Text] [Related]
2. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics.
Dimberg LY; Anderson CK; Camidge R; Behbakht K; Thorburn A; Ford HL
Oncogene; 2013 Mar; 32(11):1341-50. PubMed ID: 22580613
[TBL] [Abstract][Full Text] [Related]
3. TRAIL on trial: preclinical advances in cancer therapy.
Stuckey DW; Shah K
Trends Mol Med; 2013 Nov; 19(11):685-94. PubMed ID: 24076237
[TBL] [Abstract][Full Text] [Related]
4. Death receptors as targets for anti-cancer therapy.
Papenfuss K; Cordier SM; Walczak H
J Cell Mol Med; 2008 Dec; 12(6B):2566-85. PubMed ID: 19210756
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor as an antineoplastic agent: pitfalls and promises.
Mueller H
Cell Mol Life Sci; 1998 Dec; 54(12):1291-8. PubMed ID: 9893706
[TBL] [Abstract][Full Text] [Related]
6. Self-assembled peptide nanostructures targeting death receptor 5 and encapsulating paclitaxel as a multifunctional cancer therapy.
Moyer TJ; Chen F; Toft DJ; Ruff Y; Cryns VL; Stupp SI
ACS Biomater Sci Eng; 2019 Nov; 5(11):6046-6053. PubMed ID: 33304996
[TBL] [Abstract][Full Text] [Related]
7. Dependence receptors: new targets for cancer therapy.
Brisset M; Grandin M; Bernet A; Mehlen P; Hollande F
EMBO Mol Med; 2021 Nov; 13(11):e14495. PubMed ID: 34542930
[TBL] [Abstract][Full Text] [Related]
8. The long road to TRAIL therapy: a TRAILshort detour.
Chandrasekar AP; Maynes M; Badley AD
Oncotarget; 2021 Mar; 12(7):589-591. PubMed ID: 33868580
[No Abstract] [Full Text] [Related]
9. Paclitaxel promotes a caspase 8-mediated apoptosis through death effector domain association with microtubules.
Mielgo A; Torres VA; Clair K; Barbero S; Stupack DG
Oncogene; 2009 Oct; 28(40):3551-62. PubMed ID: 19668227
[TBL] [Abstract][Full Text] [Related]
10. To kill a tumor cell: the potential of proapoptotic receptor agonists.
Ashkenazi A; Herbst RS
J Clin Invest; 2008 Jun; 118(6):1979-90. PubMed ID: 18523647
[TBL] [Abstract][Full Text] [Related]
11. TRAIL and chemotherapeutic drugs in cancer therapy.
Wu XX; Ogawa O; Kakehi Y
Vitam Horm; 2004; 67():365-83. PubMed ID: 15110186
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR
Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135
[TBL] [Abstract][Full Text] [Related]
13. Modulation of TRAIL signaling for cancer therapy.
Fulda S; Debatin KM
Vitam Horm; 2004; 67():275-90. PubMed ID: 15110182
[TBL] [Abstract][Full Text] [Related]
14. Additive effects of TRAIL and paclitaxel on cancer cells: implications for advances in cancer therapy.
Odoux C; Albers A
Vitam Horm; 2004; 67():385-407. PubMed ID: 15110187
[TBL] [Abstract][Full Text] [Related]
15. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
16. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
